Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venipuncture.~* Body mass index (BMI) between 18 and 30 kg/m2 (inclusive) and weight at least 50 kg but no more than 100 kg.~Exclusion Criteria:~* Clinically significant medical history including severe allergies or a history of mental disorders or any cardiac history, history or presence of gastrointestinal, hepatic, or renal disease.~* Abnormal heart rhythm including any abnormal arrhythmias, marked sinus arrhythmias, or junctional rhythms.~* Known or suspected history of drug abuse, current smokers or those who have smoked and/or used nicotine products within 3 months prior to enrollment.~* Excessive intake of caffeine-containing products

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): NKTR-118 25 mg (1x25 mg tablet + 5x placebo tablets)
- B (Type: EXPERIMENTAL): NKTR-118 150 mg (6x25 mg tablet)
- C (Type: PLACEBO_COMPARATOR): NKTR-118 placebo (6x placebo tablets)
- D (Type: ACTIVE_COMPARATOR): Moxifloxacin (1 x 400 mg tablet)

Based on this trial design, predict the completion outcome and termination type (if applicable).